COTTONWOOD HEIGHTS, UT / ACCESSWIRE / March 12, 2019 / Dynatronics Corporation (NASDAQ: DYNT), a leading provider of physical therapy, rehabilitation, and athletic training products, today announced that its management team will attend the ROTH 2019 Conference being held March 17-19, 2019 in Dana Point, California.
ROTH’s 31st annual conference brings together over 550 public and private companies in a variety of industries. The conference attracts over 4,700 attendees, including institutional investors, private equity investors, and venture capital investors focused on the small and mid-cap markets. Investors attending the conference who would like to schedule a one-on-one meeting with Dynatronics management may do so by contacting their ROTH representative, or Jim Ogilvie at jim.ogilvie@dynatronics.com.
“We are pleased to have the opportunity to attend the ROTH Conference for the fourth time,” said Dr. Christopher R. von Jako, CEO of Dynatronics. “This conference has proven to be a valuable tool for us to reach investors focused on both our size and market segment.”
About Dynatronics Corporation
Dynatronics is a medical device company committed to providing high-quality restorative products designed to accelerate one to their optimal health. The company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. The company is headquartered in greater Salt Lake City, Utah, and its products are marketed under a portfolio of brands including Bird & Cronin®, Dynatron Solaris®, Hausmann, Physician’s Choice®, and PROTEAM™. More information is available at www.dynatronics.com.
Contact:
Dynatronics Corporation
Investor Relations
Jim Ogilvie
(801) 727-1755
jim.ogilvie@dynatronics.com
For additional information, please visit: www.dynatronics.com
Like Dynatronics on Facebook
Connect with Dynatronics on LinkedIn
Follow us on Twitter
SOURCE: Dynatronics Corporation
View source version on accesswire.com:
https://www.accesswire.com/538681/Dynatronics-to-Participate-in-2019-ROTH-Conference-in-Dana-Point-California
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people…
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary…
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median…
Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV)…
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal…
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="600px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
